

References

1. Simon JE, Parboosingh J, Clark A, George D, Lafontaine AL, Hill MD. A 52-year-old man with cognitive decline, seizure and stroke. *CMAJ* 2004;170(9):1393-4.
2. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004;291:565-75.
3. Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. *JAMA* 1997;277:813-7.

Competing interests: None declared.

DOI:10.1503/cmaj.1041166

Genetics and insurance

I was pleased to read the commentary by Bartha Knoppers and Yann Joly¹ and the accompanying article by the Canadian Genetics and Life Insurance Task Force.² I agree that there is an urgent need to systematically address the issues of genetic risk and insurability in the Canadian context. Although 90% of people are insured at standard premi-

ums,¹ there is a growing perception among many of those who undergo predictive (presymptomatic) testing that their test results may have negative consequences.

Consider the following recent clinical scenarios: a health care provider who works full-time for an insurance company requests anonymous testing for *BRCA1* (a gene associated with higher risk of breast and ovarian cancer); a man at risk for a neurodegenerative disease registers in a genetics clinic under an assumed name and pays out-of-pocket for genetic counselling and DNA testing; a specialist uses a code word indicating a positive result on a genetic test when referring a patient for prophylactic surgery; women with positive test results for *BRCA1* or *BRCA2* request that no copies of test results or medical recommendations be sent to their physicians; other women at risk for *BRCA1* or *BRCA2* either decline to undergo testing or refuse to disclose the results of testing to relatives (including children).

Fear of insurance discrimination is adversely affecting medical care in this country because patients in such situations perceive that the results of genetic testing could compromise their ability to obtain insurance. Whether the risk is real or imagined, the *perception* of risk is preventing these patients from accessing appropriate care. I wholeheartedly support a moratorium on the use of genetic information by insurance companies and the formation of an independent body to study the issue and make recommendations.

Wendy S. Meschino

Clinical Geneticist and Associate Chief Genetics Program
North York General Hospital
Toronto, Ont.

References

1. Knoppers BM, Joly Y. Physicians, genetics and life insurance. *CMAJ* 2004;170(9):1421-3.
2. Knoppers BM, Lemmens T, Godard B, Joly Y, Avaré D, Clark T, et al. Genetics and life insurance in Canada: points to consider. *CMAJ* 2004;170(9):Online-1 to Online-3. Available: www.cmaj.ca/cgi/data/170/9/1421/DC2/1 (accessed 2004 Jun 23).

Competing interests: None declared.

DOI:10.1503/cmaj.1040969

Correction

In an article about cervical cancer mortality in Canada by Edward Ng and associates,¹ the 3-year moving mortality averages were based on data obtained from the International Agency for Research on Cancer. The agency name was given incorrectly in the Methods section and in the cited reference (reference 9 in the original article). The correct information appears in the second reference² in this correction.

References

1. Ng E, Wilkins R, Fung MFK, Berthelot JM. Cervical cancer mortality by neighbourhood income in urban Canada from 1971 to 1996. *CMAJ* 2004;170(10):1545-9.
2. World Health Organization (WHO), International Agency for Research on Cancer (IARC). *Cancer mortality database* [based on WHO mortality data updated 2001 Nov]. Lyon, France: IARC. Available: www-dep.iarc.fr/dataava/infodata.htm (accessed 2004 Feb 12).

DOI:10.1503/cmaj.1041188

New letters submission process

CMAJ's enhanced eLetters feature is now the portal for all submissions to our letters column. To prepare an eLetter, visit www.cmaj.ca and click "Submit a response to this article" in the box near the top right-hand corner of any *eCMAJ* article. All eLetters will be considered for publication in the print journal.

Letters written in response to an article published in *CMAJ* are more likely to be accepted for print publication if they are submitted within 2 months of the article's publication date. Letters accepted for print publication are edited for length (usually 250 words) and house style.

Nouveau mécanisme de présentation des lettres

Le site amélioré des cyberlettres du *JAMC* est désormais le portail de réception de tous les textes destinés à la chronique Lettres. Pour rédiger une cyberlettre, consultez un article sur le site www.jamc.ca et cliquez ensuite sur le lien «Lettres électroniques : répondre à cet article», dans la boîte en haut à droite de l'article. Toutes les cyberlettres seront étudiées pour une éventuelle publication dans le journal imprimé.

Les lettres répondant à un article publié dans le *JAMC* sont plus susceptibles d'être acceptées pour publication imprimée si elles sont présentées dans les deux mois de la date de publication de l'article. Les lettres acceptées pour publication imprimée sont révisées en fonction du style du *JAMC* et raccourcies au besoin (elles doivent habituellement compter au maximum 250 mots).